Group 1 - The core point of the announcement is the approval of the "2025 Restricted Stock Incentive Plan (Draft)" by the Supervisory Board, aimed at enhancing the company's long-term incentive mechanism to attract and retain talent while aligning the interests of shareholders, the company, and core team members [1][2] - The Supervisory Board believes that the plan complies with relevant laws and regulations, ensuring that the interests of the company and all shareholders are not harmed, and it will contribute to the sustainable development of the company [2][3] - The voting result for the incentive plan was unanimous approval with 3 votes in favor, and it will be submitted to the shareholders' meeting for further approval [2][3] Group 2 - The "2025 Restricted Stock Incentive Plan Implementation Assessment Management Measures" was also approved, which aligns with the company's development strategy and operational goals, ensuring the effective implementation of the incentive plan [3][4] - The assessment indicators within the management measures are deemed scientific, reasonable, and comprehensive, providing constraints on the incentivized individuals to achieve the assessment objectives [3][4] - The voting result for the assessment management measures was also unanimous approval with 3 votes in favor, and it will be submitted to the shareholders' meeting for further approval [3][4] Group 3 - The company plans to add its wholly-owned subsidiary, Changhua Chemical Technology (Lianyungang) Co., Ltd., as an implementation entity for the fundraising project "Information System Construction," expanding the project location [5][6] - This addition is expected to enhance the efficiency of fundraising usage and ensure the smooth progress of the project, ultimately maximizing project benefits and improving returns to shareholders [5][6] - The voting result for this proposal was unanimous approval with 3 votes in favor, and the sponsor, Dongwu Securities Co., Ltd., provided a no-objection special verification opinion [5][6]

Core Viewpoint - Xiamen International Trade Group Co., Ltd. is proceeding with the repurchase and cancellation of a portion of the restricted stock from its 2022 incentive plan, following necessary approvals and in compliance with relevant regulations [1][4][8]. Group 1: Approval and Authorization - The company held a shareholders' meeting on April 12, 2022, where it approved the 2022 incentive plan and authorized the board to handle necessary matters related to the repurchase and cancellation of restricted stock [4]. - The board and supervisory board meetings on June 17, 2025, also approved the proposal for the repurchase and cancellation of restricted stock [5]. Group 2: Details of the Repurchase and Cancellation - A total of 29,842,451 shares will be repurchased and canceled due to various reasons, including retirement, job transfers, and failure to meet performance targets [6][7]. - The repurchase price for the shares is set at 4.50 yuan per share for the initial grant and 4.92 yuan per share for the reserved grant, with adjustments for interest in certain cases [7][8]. Group 3: Compliance and Next Steps - The repurchase and cancellation process must adhere to the disclosure requirements and procedures outlined in the relevant regulations and laws [8]. - The legal opinion confirms that the necessary approvals have been obtained and that the actions are in compliance with the applicable management measures and the 2022 incentive plan [8].

关于 2020 年限制性股票激励计划首次授予部分第四个归属期归属结果暨股票上市的公告 证券代码：300048 证券简称：合康新能 编号：2025－040 北京合康新能科技股份有限公司 关于 2020 年限制性股票激励计划首次授予部分 第四个归属期归属结果暨股票上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 北京合康新能科技股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日 召开第六届董事会第二十次会议和第六届监事会第十八次会议审议通过了《关于 近日公司完成了 2020 年限制性股票激励计划（以下简称"本激励计划"）首次授 予部分第四个归属期归属股票的登记。现将相关事项公告如下： 一、本激励计划实施情况概要 （一）本激励计划的主要内容 司召开 2021 年第一次临时股东大会，审议通过《关于 <北京合康新能科技股份有> 限公司 2020 年限制性股票激励计划（草案）>及其摘要的议案》，本激励计划主 要内容如下： ，股票来源为公司向激励对象定向发行公司 A 股普通股股票。 类限制性股票） 次及预留授予的限制性股票的归属安排 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-086 英科医疗科技股份有限公司 关于 2025 年限制性股票激励计划内幕信息知情人及 激励对象买卖公司股票情况的自查报告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于2025年5月29 日召开了第四届董事会第五次会议和第四届监事会第五次会议，会议 审议通过了《关于公司<2025年限制性股票激励计划（草案）>及其摘 要 的 议 案 》 等 相 关 议 案 ， 并 于 2025 年 5 月 30 日 在 巨 潮 资 讯 网 （www.cninfo.com.cn，下同）披露了相关公告。 一、核查的范围及程序 根据《上市公司股权激励管理办法》 （以下简称"《管理办法》 "）、 《上市公司信息披露管理办法》等有关法律、法规和规范性文件以及 公司相关内部保密制度的规定，公司对2025年限制性股票激励计划 （以下简称"激励计划"或"本激励计划" ）采取了充分必要的保密 措施，同时对本激励计划的内幕信息知情人进行了必要登记。 根据《上市公司股权激励管理办法》 《深圳证 ...

证券代码：300709 证券简称：精研科技 公告编号：2025-026 江苏精研科技股份有限公司 董事会薪酬与考核委员会关于 2025 年限制性股票激励计划首次授予 激励对象名单的公示情况说明及核查意见 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏精研科技股份有限公司（以下简称"公司"）于2025年6月5日召开第四 届董事会第六次会议和第四届监事会第六次会议，审议通过了《关于公司<2025 年限制性股票激励计划（草案）>及其摘要的议案》等相关议案，具体内容详见 公司于2025年6月6日在巨潮资讯网（www.cninfo.com.cn）披露的相关公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深 圳证券交易所创业板股票上市规则》（以下简称《上市规则》）、《深圳证券交 易所创业板上市公司自律监管指南第 1 号——业务办理》（以下简称"《自律监 管指南 1 号》"）等有关法律、法规、规范性文件及《江苏精研科技股份有限公 司章程》（以下简称"《公司章程》"）的规定，公司对 2025 年限制性股票激 励计划（以下简称"本次激励计划"）首次 ...

Core Viewpoint - Sichuan Zigong Transportation Machinery Group Co., Ltd. has announced the repurchase and cancellation of a portion of restricted stock, which will lead to a reduction in registered capital and total shares outstanding [1][3]. Group 1: Stock Repurchase and Cancellation - The company will repurchase and cancel 45,136 shares of restricted stock, which accounts for approximately 0.0192% of the total share capital [2]. - Following the cancellation, the total number of shares will decrease from 234,962,318 to 234,917,182, and the registered capital will reduce from 234,962,318 yuan to 234,917,182 yuan [3]. Group 2: Shareholder Meeting - The company held its first extraordinary general meeting of shareholders on June 16, 2025, where the proposal for the stock repurchase was approved [7][9]. - A total of 76 shareholders attended the meeting, representing 122,491,422 shares, which is 52.1323% of the total voting shares [10]. - The proposal was passed with 99.9466% approval from the attending shareholders [14]. Group 3: Debt Creditor Notification - Creditors are required to submit their claims for debt repayment or guarantees within 30 days of receiving the notification or 45 days from the announcement date if no notification is received [3][4]. - The company has outlined the necessary documentation and procedures for creditors to claim their debts [5][6].

Core Points - The company has completed the registration of its 2025 Restricted Stock Incentive Plan, granting a total of 524,000 shares to 17 incentive recipients at a price of RMB 13.44 per share [2][5][10] Group 1: Grant Details - The grant date for the restricted stock was set as May 28, 2025, with the total number of shares granted being 524,000 [5][6] - The source of the restricted stock is from the company's repurchase of its own A-shares in the secondary market [3][8] - The total cash received from the incentive recipients for the stock subscription amounted to RMB 7,042,560 [8] Group 2: Vesting and Lock-up Period - The effective period of the incentive plan lasts up to 36 months from the completion of the stock registration [6] - The lock-up periods for the granted shares are set at 12 months and 24 months from the registration completion date [6][7] Group 3: Impact on Share Structure - The total share capital of the company remains unchanged after the grant, as the shares are sourced from repurchased stock [10] - The incentive plan does not affect the shareholding ratio of the controlling shareholder or actual controller [10] Group 4: Financial Implications - The funds raised from the incentive plan will be used to supplement the company's working capital [12] - The company will recognize the cost of the restricted stock in its financial statements over the vesting period, with the estimated costs being adjusted based on the number of shares that can be released from lock-up [12][13]

Core Viewpoint - Tianchen Medical has announced adjustments to its 2022 restricted stock incentive plan, including a reduction in the grant price and the cancellation of certain unvested shares due to the departure of two incentive recipients [1][9][11] Summary by Sections Decision Process and Disclosure - The company held a board meeting on May 5, 2022, to approve the draft of the restricted stock incentive plan and related proposals, with independent directors expressing their agreement [2][3] - The company disclosed the plan on the Shanghai Stock Exchange on May 6, 2022, and conducted a public notice period for the incentive recipients from May 9 to May 18, 2022, with no objections received [3][4] Adjustments and Results - The adjusted grant price for the restricted stock is set at RMB 10.55 per share, down from RMB 12.05 per share, following a calculation that accounts for cash dividends distributed to shareholders [8][9] - The company will cancel 4,400 shares of restricted stock that were granted but not vested due to the departure of two incentive recipients [9][11] Impact on the Company - The adjustments to the grant price and the cancellation of shares are not expected to have a material impact on the company's financial status or operational results, nor will they affect the stability of the core team or the implementation of the incentive plan [9][11] Opinions from Committees - The Board's Compensation and Assessment Committee supports the adjustments, stating they comply with relevant laws and regulations, and do not harm the interests of the company or its shareholders [10][11] Legal Opinions - Legal counsel confirms that the adjustments and cancellations have received necessary approvals and comply with applicable regulations, ensuring no adverse effects on the company's financial health or incentive plan execution [11]

Core Viewpoint - The legal opinion letter from Shanghai Junlan Law Firm confirms that Tianchen International Medical Technology Co., Ltd. has complied with relevant regulations regarding the adjustment, cancellation, and vesting of its restricted stock incentive plan, ensuring that these actions do not materially impact the company's financial status or operational results [1][17]. Group 1: Approval and Authorization - The adjustments, cancellations, and vesting of the restricted stock incentive plan have received necessary approvals and authorizations from the company's board and shareholders, in accordance with the relevant management measures and regulations [3][16]. - The company has provided all necessary documents to the law firm, ensuring their authenticity and completeness, which supports the legal opinion issued [2]. Group 2: Adjustment Details - The adjustment of the grant price for the restricted stock was necessitated by the company's profit distribution plans, which included cash dividends of RMB 5.00 per 10 shares for the years 2024 and 2025 [6][7]. - The adjusted grant price for the restricted stock is set at RMB 10.75 per share, down from the previous price of RMB 12.25 per share, after accounting for the cash dividends [8][9]. Group 3: Cancellation and Vesting - A total of 168,000 shares of restricted stock were canceled due to the departure of 8 incentive recipients, who no longer qualify for the incentive program [9][10]. - The second vesting period for the incentive plan is from April 28, 2025, to April 27, 2026, with specific performance targets set for the company and individual recipients to meet [11][12]. - The company has met the performance criteria for the second vesting period, allowing 89 recipients to vest a total of 556,000 shares at the adjusted price [14][17]. Group 4: Information Disclosure - The company is required to disclose relevant information regarding the adjustments, cancellations, and vesting of the incentive plan in accordance with applicable regulations [15][16]. - The law firm confirms that the company has fulfilled its current information disclosure obligations and will continue to do so as required [15][17].

天臣国际医疗科技股份有限公司董事会薪酬与考核委员会 第三个归属期归属名单的核查意见 除 2 名激励对象因个人原因离职外，公司本次拟归属的首次授予部分 34 名 激励对象及预留授予部分 8 名激励对象均符合《公司法》《证券法》等法律、法 规和规范性文件及《公司章程》规定的任职资格，符合《管理办法》 《上市规则》 关于 2022 年限制性股票激励计划首次及预留授予部分 天臣国际医疗科技股份有限公司（以下简称"公司"）董事会薪酬与考核委 员会依据《中华人民共和国公司法》 （以下简称"《公司法》"）、 《中华人民共和 国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称 "《管理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规 则》"）、《科创板上市公司自律监管指南第 4 号——股权激励信息披露》（以下 简称"《自律监管指南》"）等相关法律、法规及规范性文件和《天臣国际医疗 （以下简称"《公司章程》"）的有关规定，对公司 2022 科技股份有限公司章程》 年限制性股票激励计划（以下简称"本激励计划"）首次及预留授予部分第三个 归属期的归属名单进行了审核，发表核查意见如下： ...